Forest submits lercanidipine NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest submits NDA Oct. 1 for its hypertension treatment lercanidipine. The calcium channel blocker, which will receive a standard review at FDA, is marketed in Europe as Zanipid. Forest licenses the product from Recordati